Not all melanomas are created equal: a review and call for more research into nodular melanoma.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
accepted:
12
04
2021
pubmed:
18
4
2021
medline:
25
2
2023
entrez:
17
4
2021
Statut:
ppublish
Résumé
Among the histogenic subtypes of melanoma, nodular melanoma (NM) is the major contributor for thicker and fatal melanomas and it has been associated with melanoma-specific death in thin tumours, highlighting an important subgroup of 'aggressive thin' melanomas. This review provides a synthesis of the distinct characteristics of NM, with respect to epidemiology and risk factors, clinical presentation, histopathology, molecular and dermoscopic aspects, and screening practices. The real challenges are to find better biomarkers of aggressiveness and to know whether the control of such aggressive melanomas can be influenced by targeted interventions such as early detection, drug interventions and preventive strategies.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
700-710Informations de copyright
© 2021 British Association of Dermatologists.
Références
Teramoto Y, Keim U, Gesierich A et al. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol 2018; 178:443-51.
Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011; 24:879-97.
Shaikh WR, Xiong M, Weinstock MA. The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007. Arch Dermatol 2012; 148:30-6.
Robsahm TE, Helsing P, Nilssen Y et al. High mortality due to cutaneous melanoma in Norway: a study of prognostic factors in a nationwide cancer registry. Clin Epidemiol 2018; 10:537-48.
Garbe C, Amaral T, Peris K et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. Eur J Cancer 2020; 126:141-58.
Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas in the United States: beware of the nodular subtype. Arch Dermatol 2005; 141:745-50.
Criscione VD, Weinstock MA. Melanoma thickness trends in the United States, 1988-2006. J Invest Dermatol 2010; 130:793-7.
Linos E, Swetter SM, Cockburn MG et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129:1666-74.
Shaikh WR, Dusza SW, Weinstock MA et al. Melanoma thickness and survival trends in the United States, 1989 to 2009. J Natl Cancer Inst 2016; 108:djv294. https://doi.org/10.1093/jnci/djv294.
Fujisawa Y, Yoshikawa S, Minagawa A et al. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med 2019; 8:2146-56.
Mar V, Roberts H, Wolfe R et al. Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. J Am Acad Dermatol 2013; 68:568-75.
Minini R, Rohrmann S, Braun R et al. Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the Canton of Zurich, Switzerland. Melanoma Res 2017; 27:145-51.
Smithson SL, Pan Y, Mar V. Differing trends in thickness and survival between nodular and non-nodular primary cutaneous melanoma in Victoria, Australia. Med J Aust 2015; 203:20.
Dessinioti C, Geller AC, Stergiopoulou A et al. Association of skin examination behaviors and thinner nodular vs superficial spreading melanoma at diagnosis. JAMA Dermatol 2018; 154:544-53.
Liu W, Dowling JP, Murray WK et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006; 142:1551-8.
Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol 2016; 136:1161-71.
Sacchetto L, Zanetti R, Comber H et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018; 92:108-18.
Hollestein LM, van den Akker SA, Nijsten T et al. Trends of cutaneous melanoma in the Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2012; 23:524-30.
Monshi B, Vujic M, Kivaranovic D et al. The burden of malignant melanoma - lessons to be learned from Austria. Eur J Cancer 2016; 56:45-53.
Helvind NM, Holmich LR, Smith S et al. Incidence of in situ and invasive melanoma in Denmark from 1985 through 2012: a national database study of 24,059 melanoma cases. JAMA Dermatol 2015; 151:1087-95.
Ghazawi FM, Cyr J, Darwich R et al. Cutaneous malignant melanoma incidence and mortality trends in Canada: a comprehensive population-based study. J Am Acad Dermatol 2019; 80:448-59.
Lattanzi M, Lee Y, Simpson D et al. Primary melanoma histologic subtype: impact on survival and response to therapy. J Natl Cancer Inst 2019; 111:180-8.
Green AC, Viros A, Hughes MCB et al. Nodular melanoma: a histopathologic entity? Acta Derm Venereol 2018; 98:460-2.
Lindholm C, Andersson R, Dufmats M et al. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer 2004; 101:2067-78.
Carrera C, Gual A, Diaz A et al. Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians. Melanoma Res 2017; 27:315-20.
Hugdahl E, Kalvenes MB, Puntervoll HE et al. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br J Cancer 2016; 114:801-8.
Egger ME, Dunki-Jacobs EM, Callender GG et al. Outcomes and prognostic factors in nodular melanomas. Surgery 2012; 152:652-9; discussion 659-60.
Green AC, Baade P, Coory M et al. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 2012; 30:1462-7.
Claeson M, Baade P, Brown S et al. Clinicopathological factors associated with death from thin (≤ 1.00 mm) melanoma. Br J Dermatol 2020; 182:927-31.
Dessinioti C, Dimou N, Geller AC et al. Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. J Natl Cancer Inst 2019; 111:1314-22.
El Sharouni MA, van Diest PJ, Witkamp AJ et al. Subtyping cutaneous melanoma matters. JNCI Cancer Spectr 2020; 4:pkaa097.
Balch CM, Balch GC, Sharma RR. Identifying early melanomas at higher risk for metastases. J Clin Oncol 2012; 30:1406-7.
Geller AC, Swetter SM, Weinstock MA. Focus on early detection to reduce melanoma deaths. J Invest Dermatol 2015; 135:947-9.
Cochran AJ, Bastian BC, Elder DE. Nodular melanoma. In: WHO Classification of Skin Tumours (Elder DE, Massi D, Scolyer RA, Willemze R, eds), 4th edn, vol. 11. Lyon, France: International Agency for Research on Cancer (IARC), 2018; 145-6.
Elder DE, Bastian BC, Cree IA et al. The 2018 World Health Organization Classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 2020; 144:500-22.
Caini S, Gandini S, Sera F et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer 2009; 45:3054-63.
Bay C, Kejs AM, Storm HH, Engholm G. Incidence and survival in patients with cutaneous melanoma by morphology, anatomical site and TNM stage: a Danish population-based register study 1989-2011. Cancer Epidemiol 2015; 39:1-7.
Chamberlain AJ, Fritschi L, Giles GG et al. Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol 2002; 138:609-14.
Geller AC, Elwood M, Swetter SM et al. Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia. Cancer 2009; 115:1318-27.
Pandeya N, Kvaskoff M, Olsen CM et al. Factors related to nevus-associated cutaneous melanoma: a case-case study. J Invest Dermatol 2018; 138:1816-24.
Dessinioti C, Geller AC, Stergiopoulou A et al. Nevus count associations with thinner nodular or superficial spreading melanoma. Acta Derm Venereol 2019; 99:614-5.
Geller AC, Mayer JE, Sober AJ et al. Total nevi, atypical nevi, and melanoma thickness: an analysis of 566 patients at 2 US centers. JAMA Dermatol 2016; 152:413-8.
Cadby G, Ward SV, Cole JM et al. The association of host and genetic melanoma risk factors with Breslow thickness in the Western Australian Melanoma Health Study. Br J Dermatol 2014; 170:851-7.
Ribero S, Davies JR, Requena C et al. High nevus counts confer a favorable prognosis in melanoma patients. Int J Cancer 2015; 137:1691-8.
Crocetti E, Caldarella A, Chiarugi A et al. The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past. Melanoma Res 2010; 20:422-6.
Shen S, Wolfe R, McLean CA et al. Characteristics and associations of high-mitotic-rate melanoma. JAMA Dermatol 2014; 150:1048-55.
Menzies SW, Moloney FJ, Byth K et al. Dermoscopic evaluation of nodular melanoma. JAMA Dermatol 2013; 149:699-709.
Kalkhoran S, Milne O, Zalaudek I et al. Historical, clinical, and dermoscopic characteristics of thin nodular melanoma. Arch Dermatol 2010; 146:311-18.
Chamberlain AJ, Fritschi L, Kelly JW. Nodular melanoma: patients’ perceptions of presenting features and implications for earlier detection. J Am Acad Dermatol 2003; 48:694-701.
Greenwald HS, Friedman EB, Osman I. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res 2012; 22:1-8. https://doi.org/10.1097/CMR.0b013e32834e6aa0.
Thomas NE, Kricker A, Waxweiler WT et al. Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. JAMA Dermatol 2014; 150:1306-14.
Wee E, Wolfe R, McLean C et al. Clinically amelanotic or hypomelanotic melanoma: anatomic distribution, risk factors, and survival. J Am Acad Dermatol 2018; 79:645-51 e644.
Lallas A, Zalaudek I, Apalla Z et al. Management rules to detect melanoma. Dermatology 2013; 226:52-60.
Kelly JW. Nodular melanoma: how current approaches to early detection are failing. J Drugs Dermatol 2005; 4:790-3.
Grob JJ, Bonerandi JJ. The ‘ugly duckling’ sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998; 134:103-4.
Moynihan GD. The 3 Cs of melanoma: time for a change? J Am Acad Dermatol 1994; 30:510-11.
Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705-27.
Scolyer RA, Judge MJ, Evans A et al. Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol 2013; 37:1797-814.
College of American Pathologists. Protocol for the examination of specimens from patients with melanoma of the skin. Version: Melanoma Biopsy 4.2.0.0. April 2020. Available at: https://documents.cap.org/protocols/cp-skin-melanoma-biopsy-20-4200.pdf (accesssed 2 June 2021)
Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol 2011; 5:124-36.
Kelly JW, Chamberlain AJ, Staples MP, McAvoy B. Nodular melanoma. No longer as simple as ABC. Aust Fam Physician 2003; 32:706-9.
Cymerman RM, Shao Y, Wang K et al. De novo vs nevus-associated melanomas: differences in associations with prognostic indicators and survival. J Natl Cancer Inst 2016; 108:djw121. https://doi.org/10.1093/jnci/djw121.
Martin-Gorgojo A, Requena C, Garcia-Casado Z et al. Dysplastic vs. common naevus-associated vs. de novo melanomas: an observational retrospective study of 1,021 patients. Acta Derm Venereol 2018; 98:556-62.
Pan Y, Adler NR, Wolfe R et al. Nodular melanoma is less likely than superficial spreading melanoma to be histologically associated with a naevus. Med J Aust 2017; 207:333-8.
Haenssle HA, Mograby N, Ngassa A et al. Association of patient risk factors and frequency of nevus-associated cutaneous melanomas. JAMA Dermatol 2016; 152:291-8.
Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:472-92.
Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 2018; 25:2105-10.
Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma of the skin. In: AJCC Cancer Staging Manual (Amin MB, Edge S, Greene F et al., eds). Switzerland: Springer, 2017, 563-85.
Kashani-Sabet M, Miller JR 3rd, Lo S et al. Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. Cancer 2020; 126:4717-25.
Wheless L, Isom CA, Hooks MA, Kauffmann RM. Mitotic rate is associated with positive lymph nodes in patients with thin melanomas. J Am Acad Dermatol 2018; 78:935-41.
von Schuckmann LA, Hughes MCB, Lee R et al. Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system. J Am Acad Dermatol 2019; 80:272-4.
Landi MT, Bishop DT, MacGregor S et al. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nat Gen 2020; 52:494-504.
Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011; 164:776-84.
Argenziano G, Longo C, Cameron A et al. Blue-black rule: a simple dermoscopic clue to recognize pigmented nodular melanoma. Br J Dermatol 2011; 165:1251-5.
Segura S, Pellacani G, Puig S et al. In vivo microscopic features of nodular melanomas: dermoscopy, confocal microscopy, and histopathologic correlates. Arch Dermatol 2008; 144:1311-20.
Sgouros D, Lallas A, Kittler H et al. Dermatoscopic features of thin (≤2 mm Breslow thickness) vs. thick (>2 mm Breslow thickness) nodular melanoma and predictors of nodular melanoma versus nodular non-melanoma tumours: a multicentric collaborative study by the International Dermoscopy Society. J Eur Acad Dermatol Venereol 2020; 34:2541-7. https://doi.org/10.1111/jdv.16815.
Winkler JK, Sies K, Fink C et al. Melanoma recognition by a deep learning convolutional neural network - performance in different melanoma subtypes and localisations. Eur J Cancer 2020; 127:21-9. https://doi.org/10.1016/j.ejca.2019.11.020.
Longo C, Farnetani F, Ciardo S et al. Is confocal microscopy a valuable tool in diagnosing nodular lesions? A study of 140 cases. Br J Dermatol 2013; 169:58-67.
Corneli P, Zalaudek I, Magaton Rizzi G, di Meo N. Improving the early diagnosis of early nodular melanoma: can we do better? Expert Rev Anticancer Ther 2018; 18:1007-12.
Guitera P, Menzies SW, Argenziano G et al. Dermoscopy and in vivo confocal microscopy are complementary techniques for diagnosis of difficult amelanotic and light-coloured skin lesions. Br J Dermatol 2016; 175:1311-19.
Swetter SM, Pollitt RA, Johnson TM et al. Behavioral determinants of successful early melanoma detection: role of self and physician skin examination. Cancer 2012; 118:3725-34.
US Preventive Services Task Force, Grossman DC, Curry SJ et al. Behavioral counseling to prevent skin cancer: US Preventive Services Task Force recommendation statement. JAMA 2018; 319:1134-42. https://doi.org/10.1001/jama.2018.1623.
Henrikson NB, Morrison CC, Blasi PR et al. Behavioral counseling for skin cancer prevention: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2018; 319:1143-57. https://doi.org/10.1001/jama.2017.21630.
US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC et al. Screening for skin cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 316:429-35. https://doi.org/10.1001/jama.2016.8465.
Hubner J, Waldmann A, Eisemann N et al. Association between risk factors and detection of cutaneous melanoma in the setting of a population-based skin cancer screening. Eur J Cancer Prev 2018; 27:563-9.
Wernli KJ, Henrikson NB, Morrison CC et al. Screening for skin cancer in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016; 316:436-47.
Johnson MM, Leachman SA, Aspinwall LG et al. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag 2017; 4:13-37.
Carli P, De Giorgi V, Palli D et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003; 139:607-12.
Brady MS, Oliveria SA, Christos PJ et al. Patterns of detection in patients with cutaneous melanoma. Cancer 2000; 89:342-7.
Kantor J, Kantor DE. Routine dermatologist-performed full-body skin examination and early melanoma detection. Arch Dermatol 2009; 145:873-6.
Epstein DS, Lange JR, Gruber SB et al. Is physician detection associated with thinner melanomas? JAMA 1999; 281:640-3.
Coups EJ, Manne SL, Stapleton JL et al. Skin self-examination behaviors among individuals diagnosed with melanoma. Melanoma Res 2016; 26:71-6.
Pollitt RA, Geller AC, Brooks DR et al. Efficacy of skin self-examination practices for early melanoma detection. Cancer Epidemiol Biomarkers Prev 2009; 18:3018-23.
Whiteman DC, Watt P, Purdie DM et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95:806-12.
Whiteman DC, Stickley M, Watt P et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006; 24:3172-7.
Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer 2016; 16:345-58. https://doi.org/10.1038/nrc.2016.37.
Grob JJ, Garbe C, Ascierto P et al. Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? Lancet Oncol 2018; 19:e720-5.